VDF

VDF (VDF NPs) is an experimental, charge-reversal nanoparticle formulation designed for the treatment of pancreatic cancer through a combination of chemotherapy and chemodynamic therapy (CDT). The nanoparticle is constructed from an organic iron-based polysaccharide nanocarrier (FDC) composed of dextran, carboxymethyl chitosan, and ferrocene. This carrier encapsulates doxorubicin (a chemotherapeutic) and palmitoyl ascorbate (VP, a pro-oxidant). VDF NPs are designed for enhanced tumor accumulation and pH-responsive drug release via the hydrolysis of Schiff-base groups in the acidic tumor microenvironment. Once internalized, the ferrocene component catalyzes a Fenton reaction with endogenous hydrogen peroxide to generate highly toxic hydroxyl radicals (ROS), while palmitoyl ascorbate further amplifies ROS levels and depletes cellular antioxidant defenses. This synergistic approach induces apoptosis through both ROS-mediated damage and doxorubicin-induced DNA interference, while the nanoformulation helps reduce the systemic toxicity associated with doxorubicin.

Other names

VP/DOX/FDC nanoparticles